Evidence map›Paper›PMID 41074141›Full record

ArticleCell communication and signaling : CCS2025

Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB

Marta Gómez-Almería, Claudia Gonzalo-Consuegra, Carmen Rodríguez-Cueto, María Cabañas-Cotillas, Alberto Jiménez-Amor, Isabel Machín-Díaz, Matthias B Wittwer, Pawel Dzygiel, Diego Clemente, Uwe Grether and 2 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Orally bioavailable CBResearch square · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Gómez-Almería *Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain.
Claudia Gonzalo-Consuegra *Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain.
Carmen Rodríguez-CuetoDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain.
María Cabañas-CotillasCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Alberto Jiménez-AmorDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain.
Isabel Machín-DíazCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Matthias B WittwerRoche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Pawel DzygielRoche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Diego ClementeCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Uwe GretherRoche Pharma Research & Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Javier Fernández-Ruiz *Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain. jjfr@med.ucm.es.ORCID http://orcid.org/0000-0002-4490-0604
Eva de Lago *Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain. elagofem@med.ucm.es.ORCID http://orcid.org/0000-0002-6260-3777

Funding

Instituto de Salud Carlos III CB06/05/0089Instituto de Salud Carlos III PI21/00302Instituto de Salud Carlos III PI24/00447Ministerio de Ciencia e Innovación PID2021-128906OB-I00Ministerio de Ciencia e Innovación RTI-2018-098885-B-100
6 · The paper itself

Abstract

backgroundCannabinoid type 2 receptor (CB

methodsTo this end, we used two CB

resultsIn both cases, their i.p. administration improved the neurological status of these mice, preserved their spinal motor neurons and attenuated glial reactivity. They also recovered those muscle fibers denervated by the pathology in SOD-1 transgenic mice. To confirm that the efficacy of RO-6871304 is not derived from a possible BBB damage in amyotrophic lateral sclerosis mice that may allow this agonist to reach the CNS, we analyzed their concentrations in neural tissues after acute administration in both experimental models. Our data confirmed that RO-6866945 was detected in the brain, while RO-6871304 was not, whereas both compounds were found in the plasma.

conclusionsIn summary, our data suggest that CB

Indexed as

Amyotrophic Lateral SclerosisBlood-Brain BarrierReceptor, Cannabinoid, CB2AnimalsDisease Models, AnimalDNA-Binding ProteinsMaleMiceMice, TransgenicMotor NeuronsSuperoxide Dismutase-1DNA-Binding ProteinsReceptor, Cannabinoid, CB2Superoxide Dismutase-1Tardbp protein, mouseAmyotrophic lateral sclerosisCannabinoidsCB2 receptorsEndocannabinoid systemImmune cellsMuscle compartmentsNeural compartmentsNeuroprotectionSOD-1TDP-43

Identifiers

PMID41074141
PMCPMC12513109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.